Encorafenib with binimetinib is approved by the FDA for treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation

FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation
The Food and Drug Administration approved encorafenib (Braftovi, Array BioPharma Inc., a wholly owned subsidiary of Pfizer) with binimetinib (Mektovi, Array BioPharma Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. FDA also approved the FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion diagnostics for encorafenib with binimetinib. If no mutation is detected in a plasma specimen, the tumor tissue should be tested.

Share This Post

The Food and Drug Administration (FDA) approved Encorafenib (Braftovi, Array BioPharma Inc., a wholly owned subsidiary of Pfizer) and binimetinib (Mektovi, Array BioPharma Inc.) in November 2023 as medicines that can be used to treat adults with metastatic non-small cell lung cancer (NSCLC) and a BRAF V600E mutation, which was found by an FDA-approved test.

The FDA also approved the FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion diagnostics for encorafenib in conjunction with binimetinib. Testing of the tumour tissue is necessary if a plasma specimen does not reveal any mutations.

The open-label, multicenter, single-arm PHAROS (NCT03915951) study looked at 98 people with metastatic NSCLC and the BRAF V600E mutation. The study’s effectiveness was tested on these people. Prior use of inhibitors of BRAF or MEK was prohibited. Encorafenib and binimetinib were administered to patients until disease progression or unacceptable toxicity occurred.

An independent review committee evaluated the duration of response (DoR) and objective response rate (ORR), which were the main indicators of effectiveness. The ORR was 75% (95% CI: 62, 85) among 59 treatment-naïve patients, while the median DoR was not estimable (NE) at 95% (95% CI: 23.1, NE). The ORR was 46% (95% CI: 30, 63) among 39 patients who had been treated previously, and the median DoR was 16.7 months (95% CI: 7.4, NE).

Fatigue, nausea, diarrhoea, musculoskeletal pain, vomiting, abdominal pain, visual impairment, constipation, dyspnea, dermatitis, and cough were the most frequent adverse effects (25 percent or more).

For NSCLC mutated to BRAF V600E, the recommended oral doses of encorafenib 450 mg once daily and binimetinib 45 mg twice daily are administered.

View full prescribing information for Braftovi and Mektovi.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

CAR T Cell therapy in Mumbai, India
CAR T-Cell therapy

CAR T-Cell therapy in Mumbai, India

CAR T-cell therapy, an advanced cancer treatment, is now available in Mumbai, offering hope to those suffering from some types of blood cancers. This therapy modifies a patient’s T-cells to seek out and destroy cancer cells. It is being offered by many of the leading medical centers in Mumbai, enhancing survival rates and quality of life. With advanced technology and oncologists, Mumbai is slowly becoming a hub for CAR T-cell therapy in India.

LungVax lung cancer vaccine
Lung cancer

LungVax: Lung cancer vaccine

LungVax is an innovative lung cancer vaccine designed to stimulate the immune system to target and destroy cancer cells. It is engineered to enhance the body’s natural defense mechanisms against tumor growth, offering a novel approach to lung cancer treatment. LungVax aims to prevent recurrence in high-risk patients and improve survival rates, marking a promising development in immunotherapy for one of the deadliest forms of cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy